This is similar to findings from the Chicago Multiethnic Epidemiologic Breast Cancer Cohort (ChiMEC) which reported that Black patients with early stage HER2-positive BC had lower odds of achieving pCR than White patients37. This evidence concerns the gene ERBB2 and breast carcinoma.